• where experts go to learn about FDA
  • Anne K. Walsh

    • FDA Relaxes Postmarketing Reporting Requirements During a PandemicApril 1st, 2020

      As noted in our blog post last week, FDA has issued several guidance documents authorizing the emergency use of medical devices and drugs to address the COVID-19 outbreak.  These EUAs provide a streamlined approach for selling otherwise unapproved products intended to alleviate the national emergency.  …

    • The High Costs of “Weaponizing” Discovery StrategiesOctober 25th, 2019

      What do you get when you “cross an approach to discovery à la Inspector Clouseau with a corporate lawyer caricature found in cartoon caption contests?” According to Judge Steven Rau of the District of Minnesota in a 32-page order that required an “exhaustive” 15-page factual …

    • Think Twice Before Sharing: Court Compels Disclosure of Settlement Presentations in Relator’s Qui Tam SuitOctober 7th, 2019

      In a decision that could dramatically change the course of how defendants conduct discussions with the government, a district court judge in the District of Minnesota required a defendant in a False Claims Act (FCA) case to turn over to a qui tam relator the …

    • Deference to Agency DeferenceAugust 27th, 2019

      Companies challenging FDA in court typically face a steep uphill battle given the long-standing doctrine known as Auer deference, which (in simplified terms) requires courts to defer to FDA’s interpretation of its own regulations if they are ambiguous.  The recent Supreme Court ruling in Kisor …

    • The FTC Loses Big in the Seventh CircuitAugust 26th, 2019

      In the August 21 split panel decision issued in Federal Trade Commission v. Credit Bureau Center LLC, the Seventh Circuit held that section 13(b) of the Federal Trade Commission Act (“FTCA”), 15 U.S.C. § 53(b), does not authorize an award of restitution.  In overturning its …

    • “Wine-ing” about FDA Involvement in Regulating Alcohol LabelsAugust 21st, 2019

      This case caught our eye for a few reasons, none of which directly relates to the business activities of most of our blog readers but may relate to their happy-hours activities.  As most know, FDA regulates foods, including beverages, but Congress delegated most of the …

    • Device Manufacturer’s Criminal and Civil Penalties Deserve Closer AttentionJuly 2nd, 2019

      Today’s blog post illustrates how a company’s problems can escalate rapidly from an administrative warning letter to the full weight of the criminal system.  The unfortunate subject is ACell, a manufacturer of medical devices derived from porcine urinary bladder material.  ACell received a Warning Letter …

    • SCOTUS Makes it Easier for Government to Withhold Commercial or Financial InformationJune 26th, 2019

      In a 6-3 decision, the U.S. Supreme Court reversed and remanded the lower courts’ decision to publicly disclose commercial information that previously had been submitted to the government.  Given that FDA-regulated entities often submit to FDA commercial or financial information that those entities regard as …

    • Criminal Convictions for Compounding Activities Overturned for “Legal Impossibility”June 20th, 2019

      The government lost a significant battle in its aggressive prosecutions of individuals involved in the New England Compounding Center (NECC) disaster, in which the vilified, and now-defunct, NECC “compounded” contaminated batches of drugs that led to a multitude of deaths and injuries.  Gregory Conigliaro, a …

    • Court Blesses FDA’s Rarely Used Administrative Search Warrant AuthorityMay 3rd, 2019

      A recent decision out of Pennsylvania caught our eye, not because it applied a new enforcement strategy by FDA, but to the contrary, because it relied on FDA’s “oldie but goodie” Inspection Warrant authority.  Not a search warrant, which is subject to the same “probable …

    • DOJ Guidance for Corporate Compliance Programs Parallels GMP Requirements for Drug and Device CompaniesMay 2nd, 2019

      The Department of Justice (“DOJ”) has been touting for years the common interest that government and industry share in promoting an ethical corporate culture.  This week, DOJ reinforced the importance of a robust, well-designed, and effective corporate compliance program in DOJ’s determination of whether to …

    • DOJ Should Listen to Its Own ArgumentsApril 15th, 2019

      As it previewed back in December, the government formally filed its motion to dismiss the high-profile False Claims Act case against Gilead Sciences, Inc.  This case has had a long history, beginning in 2010 when the Relators filed their original complaint.  After investigation, in 2013, …

    • Is the Government All Fired Up About Charging Individuals?April 11th, 2019

      We have long posted about the government’s threats to hold individuals liable for actions taken on behalf of their companies, for example here, but these actions remain rare and typically are reserved for egregious, repeated, and intentional criminality.  A recent indictment against two former executives, …

    • DOJ Wants It Both Ways: Case Satisfies Materiality Standard, but Still Merits DismissalDecember 20th, 2018

      Drug and device manufacturers that sell FDA-approved products reimbursed by the federal government should stay abreast of the pending Supreme Court petition in United States ex rel. Campie v. Gilead Sciences, Inc. (the factual and procedural background is summarized here and here).  In short, the …

    • Failure to File Adverse Event Reports Results in Criminal Pleas for Medical Device Company and Quality ManagerDecember 12th, 2018

      Duodenoscopes are flexible, lighted tubes that are threaded through the body into the top of the small intestine (duodenum) and allow doctors to see potential problems in the pancreas and bile ducts. Because duodenoscopes are reusable devices, they must be reprocessed (cleaned) after each use …